Literature DB >> 11115396

Biosynthesis and shedding of epiglycanin: a mucin-type glycoprotein of the mouse TA3Ha mammary carcinoma cell.

T Thingstad1, H L Vos, J Hilkens.   

Abstract

Epiglycanin is a mucin-type glycoprotein present at the surface of TA3Ha mouse mammary tumour cells. It is a long rod-like glycoprotein with a molecular mass of 500 kDa. Its function has not yet been established but its overexpression can affect cell-cell and cell-matrix adhesion. To understand better the biological function of epiglycanin, we have studied the biochemical structure and biosynthesis of epiglycanin in TA3Ha cells. Pulse-chase labelling experiments with [(3)H]threonine revealed an early precursor with a molecular mass of approx. 300 kDa containing approx. 5-10 kDa of N-linked glycans. The precursor was gradually converted into a high-molecular-mass mature form, owing mainly, if not entirely, to O-glycosylation. The mature molecule consists of two major glycoforms that differ in sialylation. Unlike secreted mucins, epiglycanin did not form cysteine-bound multimers, providing further evidence that epiglycanin belongs to the class of membrane-associated mucins. The mature form, but not the precursor form, is shed from the cell surface. The half-life of epiglycanin on the cell surface was found to be approx. 60 h. These results provide the first detailed analysis of the biochemical structure and biosynthesis of epiglycanin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11115396      PMCID: PMC1221540     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

1.  Chemical structure of epiglycanin, the major glycoprotein of the TA3-Ha ascites cell. The carbohydrate chains.

Authors:  D H Van den Eijnden; N A Evans; J F Codington; V Reinhold; C Silber; R W Jeanloz
Journal:  J Biol Chem       Date:  1979-12-10       Impact factor: 5.157

2.  Evidence that the major cell suface glycoprotein of the TA3-Ha carcinoma contains the Vicia graminea receptor sites.

Authors:  J F Codington; A G Cooper; M C Brown; R W Jeanloz
Journal:  Biochemistry       Date:  1975-02-25       Impact factor: 3.162

3.  Specificity studies of an antibody developed against a mucin-type glycoprotein.

Authors:  S Haavik; M Nilsen; T Thingstad; H Barsett; D V Renouf; E F Hounsell; J F Codington
Journal:  Glycoconj J       Date:  1999-03       Impact factor: 2.916

4.  Biosynthesis of MAM-6, an epithelial sialomucin. Evidence for involvement of a rare proteolytic cleavage step in the endoplasmic reticulum.

Authors:  J Hilkens; F Buijs
Journal:  J Biol Chem       Date:  1988-03-25       Impact factor: 5.157

5.  Further studies on the relationship between large glycoprotein molecules and allotransplantability in the TA3 tumor of the mouse: studies on segregating TA3-HA hybrids.

Authors:  J F Codington; G Klein; A G Cooper; N Lee; M C Brown; R W Jeanloz
Journal:  J Natl Cancer Inst       Date:  1978-04       Impact factor: 13.506

6.  Inhibition of mucin glycosylation by aryl-N-acetyl-alpha-galactosaminides in human colon cancer cells.

Authors:  S F Kuan; J C Byrd; C Basbaum; Y S Kim
Journal:  J Biol Chem       Date:  1989-11-15       Impact factor: 5.157

7.  Two novel mucin genes down-regulated in colorectal cancer identified by differential display.

Authors:  S J Williams; M A McGuckin; D C Gotley; H J Eyre; G R Sutherland; T M Antalis
Journal:  Cancer Res       Date:  1999-08-15       Impact factor: 12.701

8.  Further studies on the relationship between allotransplantability and the presence of the cell surface glycoprotein epiglycanin in the TA3-MM mouse mammary carcinoma ascites cell.

Authors:  S C Miller; J F Codington; G Klein
Journal:  J Natl Cancer Inst       Date:  1982-06       Impact factor: 13.506

9.  Evidence for the presence of an N-acetyllactosamine-type chain in epiglycanin.

Authors:  J F Codington; M R Deak; D M Frim; R W Jeanloz
Journal:  Arch Biochem Biophys       Date:  1986-11-15       Impact factor: 4.013

10.  Antibody to epiglycanin and radioimmunoassay to detect epiglycanin-related glycoproteins in body fluids of cancer patients.

Authors:  J F Codington; V P Bhavanandan; K J Bloch; N Nikrui; J V Ellard; P S Wang; R W Jeanloz
Journal:  J Natl Cancer Inst       Date:  1984-11       Impact factor: 13.506

View more
  4 in total

Review 1.  Mucins and blastocyst attachment.

Authors:  Amantha Thathiah; Daniel D Carson
Journal:  Rev Endocr Metab Disord       Date:  2002-05       Impact factor: 6.514

2.  Evaluation of Virus-Like Particle-Based Tumor-Associated Carbohydrate Immunogen in a Mouse Tumor Model.

Authors:  Suttipun Sungsuwan; Xuanjun Wu; Xuefei Huang
Journal:  Methods Enzymol       Date:  2017-07-26       Impact factor: 1.600

Review 3.  Altered Mucins (MUC) trafficking in benign and malignant conditions.

Authors:  Suhasini Joshi; Sushil Kumar; Amit Choudhury; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Oncotarget       Date:  2014-09-15

Review 4.  Mucins in the mucosal barrier to infection.

Authors:  S K Linden; P Sutton; N G Karlsson; V Korolik; M A McGuckin
Journal:  Mucosal Immunol       Date:  2008-03-05       Impact factor: 7.313

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.